ENOV Enovis CORP

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Orthopedic solutions via two segments—Prevention & Recovery (P&R) and Reconstructive (Recon) with global manufacturing and sales
• • New emphasis on Recon segment growth via $865.6M Lima acquisition in Jan 2024, adding digital innovation and customized hardware
• • Strategic shift: Divested Dr Comfort Footcare Solutions in Oct 2025; focus sharpened on direct sales integration and streamlined global operations
• • Notable metric: Net sales grew 6.7% to $2.248B in 2025, driven by existing business growth and favorable currency, despite $17.3M sales loss from divestitures
• • Unusual fact: Reported $1.05B goodwill impairment charge in 2025, a significant non-cash expense impacting operating loss and net loss margins

Risk Factors

• • Sarbanes-Oxley Act compliance risk from failed internal control integration at acquisitions, e.g., Lima Acquisition, possibly causing material misstatements in financial reports
• • Geopolitical risk from supply chain in China and Asia; political instability risks disrupting access to raw materials critical to manufacturing
• • Manufacturing disruption risk from equipment failure, natural disasters, terrorism, labor shortages affecting facility operations and customer order fulfillment
• • Competitive risk from superior rival technologies and products; competitors with greater resources could cause market share loss and pricing pressure
• • Financial risk of $1.7B+ outstanding debt subject to restrictive covenants limiting transactions and increasing vulnerability to economic downturns

Management Discussion & Analysis

• • Revenue $2.248B, up 5.1% YoY: P&R $1.137B (+$39M), Recon $1.111B (+$101.4M)
• • Operating loss margin worsened: P&R (32.9)% vs (29.3)%, Recon (67.5)% vs (45.0)% in 2024 due to goodwill impairments ($387.8M P&R, $662M Recon)
• • Best segment Recon: Adjusted EBITDA $239.9M (+$23M), margin stable 21.6% vs 21.5%; worst P&R operating loss margin (32.9)%
• • Cash flow: Operating cash flow $217.3M (+$103.8M), CapEx $197.4M, acquisitions $26.9M; Financing used $52.4M including $3.5M buybacks; $36.4M cash on hand
• • Forward outlook: Credit facility increased to $1.1B revolver and $700M term loan; Senior secured leverage ratio covenant of 3.50:1; risks from goodwill impairments and acquisition integration costs

What are the latest ENOV SEC filings in 2026?

Enovis CORP (ENOV) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on May 19, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ENOV file its most recent 10-K annual report?

Enovis CORP (ENOV) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ENOV 10-Q quarterly reports?

Enovis CORP (ENOV)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every ENOV 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ENOV filed recently?

Enovis CORP (ENOV)'s most recent 8-K was filed on May 19, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ENOV insider trading activity (Form 4)?

SignalX aggregates every ENOV Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ENOV file with the SEC?

Enovis CORP (ENOV) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ENOV filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Enovis CORP (ENOV).

What is ENOV's SEC CIK number?

Enovis CORP (ENOV)'s SEC CIK (Central Index Key) number is 1420800. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1420800 to look up all ENOV filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ENOV return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Enovis CORP (ENOV) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.